How should romiplostim be initiated, dosed, and monitored in a patient with chronic immune thrombocytopenia refractory to corticosteroids, splenectomy, or other immunosuppressive therapies?

Romiplostim Initiation, Dosing, and Monitoring in Refractory Chronic ITP

Start romiplostim at 1 mcg/kg subcutaneously once weekly, adjusting the dose weekly based on platelet response to maintain counts between 50-200 × 10⁹/L, with the goal of using the minimum effective dose to prevent bleeding rather than normalizing platelet counts. 1

Initiation Strategy

When to Start:

• Initiate romiplostim in patients with ITP lasting ≥3 months who are corticosteroid-dependent or have failed corticosteroids, particularly when ITP duration exceeds 1 year 2
• TPO-RAs like romiplostim should be considered as second-line therapy before splenectomy for most patients, given the long-term risks of asplenia (3-4 fold increased mortality from sepsis, thromboembolism, and malignancy) 2
• The 2019 ASH guidelines support TPO-RA use in this population, though they don't mandate a specific sequence between romiplostim and splenectomy 3

Pre-Treatment Considerations:

• Confirm primary ITP diagnosis by excluding non-immune causes and secondary ITP if not previously done 2
• Discuss treatment goals: the objective is bleeding prevention, not platelet count normalization 1
• Inform patients about the need for weekly subcutaneous injections and regular monitoring
• Romiplostim must be ordered through a limited access program directly from the manufacturer 4

Dosing Protocol

Initial Dose:

• 1 mcg/kg subcutaneously once weekly 1
• Despite one recent study suggesting higher initial doses (≥3 mcg/kg), this showed no improvement in time to platelet response compared to standard dosing and is not supported by FDA labeling 5

Dose Adjustments:

• Adjust weekly based on platelet count to maintain target of 50-200 × 10⁹/L 1
• Increase by 1 mcg/kg increments if platelet count remains <50 × 10⁹/L
• Maximum dose: 10 mcg/kg weekly (though most patients respond at mean doses of 5.9 ± 3.9 mcg/kg/week) 4
• If platelet count reaches target range at the lowest dose (1 mcg/kg/week), hold the drug and monitor closely for potential remission 2—approximately 30% of patients may achieve long-term remission off therapy 2

Critical Dosing Principles:

• Use the minimum dose necessary to maintain target platelet counts and prevent bleeding 2
• Avoid abrupt interruptions or excessive dose adjustments, as these cause platelet fluctuations, particularly with romiplostim 2
• Platelet fluctuations are more common in splenectomized patients; if this occurs, consider switching to eltrombopag 2

Monitoring Schedule

Platelet Count Monitoring:

• Weekly until stable platelet response achieved
• Expect platelet increases at week 2 (mean difference 25.71 × 10⁹/L), with progressive increases through weeks 4-8 6
• Median time to achieve >30 × 10⁹/L is approximately 7-14 days 5, 7
• Once stable, monitoring frequency can be reduced but should remain regular

Safety Monitoring:

Thrombotic Events:

• Monitor for thromboembolism, particularly portal vein thrombosis in patients with chronic liver disease 1
• In one series, 3/21 patients (14%) developed thrombotic complications including portal vein thrombosis and pulmonary embolism 8

Bone Marrow Monitoring:

• Romiplostim increases risk of reticulin fiber formation and potentially collagen fibrosis 1
• In prospective evaluation, 7% (9/131) showed progression of reticulin formation or development of collagen over 3 years 1
• Consider baseline bone marrow biopsy before starting therapy and periodic reassessment in long-term users, though specific intervals are not mandated by FDA labeling

Antibody Formation:

• If severe thrombocytopenia develops during treatment, assess for neutralizing antibodies 1

Common Pitfalls and Management

Loss of Response:

• If patient stops responding, check for neutralizing antibodies 1
• Consider switching to eltrombopag—the majority of patients respond to the alternate TPO-RA even after failing the first one 2

Adverse Events:

• Most common: headache (35-37%), arthralgia (26%), myalgia (14%), dizziness (17%), insomnia (16%) 1
• These are generally mild to moderate and do not require discontinuation
• In pediatric patients: contusion (41%), upper respiratory infections (31%), oropharyngeal pain (25%) 1

Concomitant Therapy:

• Romiplostim can be combined with rituximab; in one series, 4/5 patients receiving both were able to discontinue romiplostim within 2 months, suggesting rituximab efficacy 7
• Patients on romiplostim alone typically require maintenance therapy 7

Treatment Duration:

• Romiplostim has demonstrated sustained efficacy and tolerability for up to 156 weeks 9, 4
• Effects are transient—platelet counts decrease within 2 weeks of discontinuation 4
• Periodically attempt to hold therapy at lowest effective doses to assess for remission 2